CRISM Therapeutics hails progress in glioblastoma as loss widens
(Alliance News) - CRISM Therapeutics Corp on Friday said it is confident in its prospects, citing progress in glioblastoma, as it reported an increased loss. Read More
Price | 22.50p on 23-06-2025 | at 06:30:02
---|---|
Change | 0.00p 0% |
Buy | 25.00p |
Sell | 20.00p |
Buy / Sell CRTX Shares |
Last Trade: | Sell 500.00 at 22.00p |
Day's Volume: | 0 |
Last Close: | 23.50p |
Open: | 0.00p |
ISIN: | VGG042401262 |
Day's Range | 0.00p - 0.00p |
52wk Range: | 5.25p - 29.00p |
Market Capitalisation: | £8m |
VWAP: | 0.00p |
Shares in Issue: | 33m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Crism Thera (CRTX) Latest Trades |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Sell* | 500 | 22.00p | Ordinary |
15:45:07 - 20-Jun-25 |
Sell* | 928 | 22.00p | Ordinary |
14:44:27 - 20-Jun-25 |
Sell* | 9,048 | 23.40p | Ordinary |
12:25:34 - 20-Jun-25 |
Unknown* | 2,127 | 23.50p | Ordinary |
12:45:55 - 19-Jun-25 |
Sell* | 626 | 22.00p | Ordinary |
12:29:28 - 19-Jun-25 |
Sell* | 375 | 22.00p | Ordinary |
12:21:20 - 19-Jun-25 |
Sell* | 1,265 | 23.40p | Ordinary |
11:22:08 - 19-Jun-25 |
Sell* | 21,013 | 22.00p | Ordinary |
10:35:51 - 19-Jun-25 |
Buy* | 102 | 25.00p | Ordinary |
09:48:13 - 19-Jun-25 |
Sell* | 162 | 23.40p | Ordinary |
08:02:48 - 19-Jun-25 |
Crism Thera (CRTX) Regulatory News |
||
Date | Source | Headline |
---|---|---|
13th Jun 2025 7:00 am | RNS | Final Results for the year ended 31 December 2024 |
9th Jun 2025 7:00 am | RNS-R | Best Paper Award |
3rd Jun 2025 7:00 am | RNS | Establishment of Scientific Advisory Board |
7th Apr 2025 11:46 am | RNS | Director Dealing |
31st Mar 2025 7:00 am | RNS | Clinical Trial Update |
27th Mar 2025 7:00 am | RNS | Innovate UK Grant Award |
20th Dec 2024 7:00 am | RNS | Appointment of Specialist Clinical CRO |
18th Dec 2024 7:00 am | RNS | European Patent Grant |
19th Sep 2024 7:00 am | RNS | Interim Results |
9th Sep 2024 7:00 am | RNS | Notice of Interim Results & IMC Presentation |